Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
7
Bullish
4
Bearish
35
Neutral
7
Bullish
4
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Upcoming Result Date: Nov 02, 2026
Pfizer Limited is a major pharmaceutical company involved in the manufacture, marketing, and export of a range of pharmaceutical products, including specialized medicines across 15 therapeutic areas. It operates manufacturing facilities in Goa and Thane, contributing to its extensive global footprint with 43 facilities worldwide.
The company has a rich history in India dating back to 1950, being the first to introduce clinical research in the country. It has evolved through strategic mergers and collaboration, most recently merging with Wyeth Limited and divesting several older product lines.
Recent product launches include Betrecep for treatment of Rheumatoid Arthritis and other conditions, showcasing Pfizer's commitment to innovation in therapeutic solutions.
Pfizer Limited significantly altered its operational scope through divestitures to Mylan, impacting its branded and generic established medicines portfolio, a move indicating strategic refocus.
They continue to bolster their respiratory portfolio with various line extensions under the Corex brand, even as it phases out older formulations in response to regulatory challenges.
Pharmaceuticals & Biotechnology
Pharmaceuticals
16,913 Cr
Low Risk
23.0
37.0
2.0
4.1
5,329.05
3,590.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
481.35 | 18,416 Cr | 314.65 | 4.71 | 0.00 | 5.05 | 5.47 | 1.02 | ||
935.10 | 18,289 Cr | 61.51 | 7.06 | 0.06 | 9.39 | 10.73 | 8.02 | ||
2373.60 | 18,042 Cr | 26.61 | 5.35 | 0.34 | 17.88 | 22.30 | 16.76 | ||
1569.65 | 18,000 Cr | -11111.01 | 3.04 | 0.00 | 0.19 | 1.55 | -0.02 | ||
3760.40 | 17,203 Cr | 23.40 | 4.09 | 1.99 | 17.19 | 23.02 | 14.94 | ||
1397.75 | 17,160 Cr | 25.62 | 5.15 | 0.36 | 16.94 | 22.33 | 15.14 | ||
1163.70 | 16,145 Cr | 22.47 | 3.90 | 0.62 | 17.07 | 12.58 | 9.48 | ||
| Median: 7 Co. | — | 1397.75 | 18,000 Cr | 25.62 | 4.71 | 0.34 | 16.94 | 12.58 | 9.48 |
Pfizer Ltd (PFIZER) is currently trading at 3,697.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Pfizer Limited is a major pharmaceutical company involved in the manufacture, marketing, and export of a range of pharmaceutical products, including specialized medicines across 15 therapeutic areas. It operates manufacturing facilities in Goa and Thane, contributing to its extensive global footprint with 43 facilities worldwide. The company has a rich history in India dating back to 1950, being the first to introduce clinical research in the country. It has evolved through strategic mergers and collaboration, most recently merging with Wyeth Limited and divesting several older product lines. Recent product launches include Betrecep for treatment of Rheumatoid Arthritis and other conditions, showcasing Pfizer's commitment to innovation in therapeutic solutions. Pfizer Limited significantly altered its operational scope through divestitures to Mylan, impacting its branded and generic established medicines portfolio, a move indicating strategic refocus. They continue to bolster their respiratory portfolio with various line extensions under the Corex brand, even as it phases out older formulations in response to regulatory challenges.
Over the past 52 weeks, Pfizer Ltd has traded between a low of ₹3,590.00 and a high of ₹5,329.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Pfizer Ltd has a market capitalization of approximately 17,202.98. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Pfizer Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.40 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 17,202.98 Cr, Pfizer Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Pfizer Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Pfizer Ltd is 23.40. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Pfizer Limited’s 75th AGM is scheduled for Tuesday, July 28, 2026 at 3:00 p.m. IST, to be held via VC/OAVM.
Pfizer Limited reported net profit of ₹204.47 crore in Q1FY27, up 6.6% year-on-year from ₹191.75 crore.
Pfizer informed BSE that its board meeting was scheduled for May 12, 2026 to consider and take on record results for the quarter and year ended March 31, 2026 and consider dividend, if any.
Shareholders reelected 12 directors, ratified KPMG as auditor for fiscal 2026, approved the amended Pfizer 2019 Stock Plan, and approved executive compensation on an advisory basis.
